



Amarin Corporation plc
Investor Relations Department
2 Pembroke House, Upper
Pembroke
Street 28-32
Dublin 2
Ireland

[Visit IR website](#)
[Sign-up for Email alerts](#)

NASDAQ: AMRN

| | |
|---------------|----------------------------|
| Last Trade: | 3.40 |
| Trade Time: | 4:00 PM ET Oct 20, 2017 |
| Change: | 0.02 (+0.592%) |
| Day Range | 3.36 - 3.49 |
| 52-Week Range | 2.75 - 4.47 |
| Volume | 1,976,146 |

Stock information is provided by eSignal,
stock charts provided by EDGAR Online.
Stock data is delayed approximately 20
minutes.

Company Profile

Amarin is conducting a cardiovascular outcomes study designed to evaluate the efficacy of Vascepa® in reducing cardiovascular events in a high-risk patient population on statin therapy called the REDUCE-IT trial.

Amarin is headquartered in Dublin, Ireland. Amarin's U.S. office is in Bedminster, New Jersey. Amarin is listed in the U.S. on NASDAQ (symbol: "AMRN").

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 25, 2017 [Amarin and HLS Therapeutics Announce Agreement to Commercialize Vascepa® in Canada](#)
- Sep 20, 2017 [Amarin to Present at Cantor Global Healthcare Conference](#)
- Sep 13, 2017 [Amarin Appoints Mark W. Salyer to New Position of Chief Commercial Officer](#)
- Sep 6, 2017 [Amarin to Present at Rodman & Renshaw's Global Investment Conference](#)
- Aug 14, 2017 [Amarin's REDUCE-IT Cardiovascular Outcomes Study of Vascepa to Continue as Planned at Recommendation of Independent Data Monitoring Committee](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 1, 2017 [Annual Report \(10-K\)](#)
- Apr 21, 2017 [Proxy Statement \(DEF 14A\)](#)
- Aug 2, 2017 [Quarterly Report \(10-Q\)](#)
- May 3, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 3, 2016 [Quarterly Report \(10-Q\)](#)